Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Skyrizi Market Expected To Reach $ Billion By 2030 At % CAGR
The expansion during the historical timeframe was driven by a higher number of autoimmune disorder diagnoses, the shortcomings of traditional immunosuppressive treatments, the growing use of biologics in dermatology and gastroenterology, enhanced availability of specialist healthcare, and improved achievement rates in clinical trials.
Expansion into new inflammatory indications, higher investments in next-generation biologics, a growing patient preference for convenient dosing schedules, an intensified healthcare emphasis on achieving durable remission, and the broadening of biologic treatment guidelines are driving the growth during the forecast period. Key trends shaping this period include the increasing adoption of IL-23-targeted therapies, expanded use across various autoimmune conditions, a rising preference for biologics with extended dosing intervals, a growing availability of self-administered injectable formats, and an enhanced focus on sustained long-term disease management.
Download A Free Sample Report For Comprehensive Market Insights:
Skyrizi Market Growth Drivers And Industry Catalysts
The increasing focus on personalized medicine is anticipated to boost the growth of the skyrizi market moving forward. This medical approach customizes treatments and healthcare strategies to each patient’s unique attributes, including their genetic profile, environment, and lifestyle, aiming to deliver the most effective and precise results. The rise of personalized medicine stems from progress in genomic technologies, a deeper grasp of molecular biology, broader access to advanced diagnostic tools, and the need for targeted therapies that enhance patient outcomes while reducing adverse effects. Skyrizi supports this trend by providing a specific biologic treatment that blocks interleukin-23 (IL-23), allowing medical professionals to customize care for patients suffering from moderate to severe autoimmune conditions such as psoriasis and ulcerative colitis, adapting to individual reactions and disease traits to boost effectiveness and limit treatment-related harms. As an example, according to the Personalized Medicine Coalition—a US-based hospital and healthcare organization—in February 2024, the FDA approved 16 new personalized therapies for rare disease patients in 2023, compared to six in 2022. Hence, the rising enthusiasm for personalized medicine is fueling the skyrizi market.
Skyrizi Market Segmentation Trends And Revenue Drivers
The skyrizi market covered in this report is segmented –
1) By Indication: Plaque Psoriasis, Crohn’s Disease, Ulcerative Colitis
2) By Formulation: Pre-Filled Syringes, Vials
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Skyrizi Market Trends Influencing Long-Term Demand
Key players in the SKYRIZI market are concentrating on advancing innovative approaches, including interleukin-23 (IL-23) inhibitor therapies, to address the growing need for precise and highly effective treatments for autoimmune and chronic inflammatory conditions. These IL-23 inhibitors function by specifically targeting the p19 subunit of the IL-23 cytokine, a critical driver of inflammatory processes. This precise mechanism provides enhanced effectiveness and a better safety profile when compared with conventional broad-spectrum immunosuppressive drugs. As an example, in July 2024, AbbVie Inc., a biopharmaceutical firm based in the United States, secured approval from the European Commission for SKYRIZI (risankizumab) to treat adults with moderately to severely active ulcerative colitis who have shown inadequate response or intolerance to conventional or biologic therapies. SKYRIZI, a monoclonal antibody that specifically inhibits IL-23, operates through a targeted mode of action to decrease inflammation and facilitate mucosal healing. The treatment protocol includes a 1,200 mg intravenous induction dose, followed by 180 mg or 360 mg subcutaneous maintenance doses administered every eight weeks. Data from the Phase 3 INSPIRE and COMMAND trials revealed robust results, such as notable mucosal healing and sustained remission, particularly among patients who had not previously used biologics or JAK inhibitors.
Skyrizi Market Industry Leaders: Which Organizations Are Driving Competition?
Major companies operating in the skyrizi market are AbbVie Inc.
Access The Complete Skyrizi Market Report:
Skyrizi Market Leading Geography: Which Region Generates The Most Revenue?
North America was the largest region in the skyrizi market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the skyrizi market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model